TOCILIZUMAB
- UNII: I031V2H011
- Preferred Substance Name: TOCILIZUMAB
- 375823-41-9
- ACTEMRA
- ATLIZUMAB
- BAT1806
- BAT-1806
- BIIB800
- BIIB-800
- IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER
- IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER
- MRA
- MSB11456
- MSB-11456
- R-1569
- RG-1569
- RGB19
- RGB-19
- RHPM-1
- RO-4877533
- ROACTEMRA
- TOCILIZUMAB (GENETICAL RECOMBINATION)
- TOCILIZUMAB [EMA EPAR]
- TOCILIZUMAB [INN]
- TOCILIZUMAB [JAN]
- TOCILIZUMAB [MART.]
- TOCILIZUMAB [MI]
- TOCILIZUMAB [PURPLE BOOK CDER]
- TOCILIZUMAB [USAN]
- TOCILIZUMAB [VANDF]
- TOCILIZUMAB [WHO-DD]
- TOCILIZUMAB BIOSIMILAR (BAT-1806)
- TOCILIZUMAB BIOSIMILAR (MSB11456)
- TOCILIZUMAB BIOSIMILAR (RGB-19)
- TOCILIZUMAB-AAZG
- TOCILIZUMAB-BAVI
- TOFIDENCE
- TYENNE
About, Contact Us, Copyright, Privacy, Accessibility
U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002
U.S. Food and Drug Administration, Health & Human Services
Powered by
